Trials / Completed
CompletedNCT00595686
Safety And Pharmacology Of SNX-5422 Mesylate In Subjects With Refractory Hematological Malignancies
A Phase 1, Open-label, Dose-Escalation Study Of The Safety And Pharmacokinetics Of SNX-5422 Mesylate In Subjects With Refractory Hematological Malignancies
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 25 (actual)
- Sponsor
- Esanex Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Hsp90 is a chemical in the body that is involved in the promotion of cancer. SNX-5422 is an experimental drug that blocks Hsp90. It is being evaluated for safety and efficacy in patients with cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SNX-5422 | dose escalated; tablets every other day; undetermined duration until disease progression |
Timeline
- Start date
- 2008-01-01
- Primary completion
- 2010-05-01
- Completion
- 2010-05-01
- First posted
- 2008-01-16
- Last updated
- 2012-05-17
Locations
4 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00595686. Inclusion in this directory is not an endorsement.